AMERICAN CHINESE SOCIETY OF TOXICOLOGY

NEWSLETTER

中国旅美毒理学家协会会刊

No. 2, 2003 **Thirty issues in total** **December 2003**

Table of Content

The editor for this issue: Haizhou Zhang

****

President's Message

Zhihua Zhang

It is time of the year again. Although all of us may be very busy in our work or study, I am sure that everyone is enjoying the holiday season atmosphere because the holiday decorations are up and the holiday music is on. Do not mention the holiday parties. As the current president of ACSOT, I wish all members and friends have a happy holiday and happy New Year. I also would take this opportunity to report our accomplishments for the past year and look into what is ahead next year.

As many of you have known that ACSOT and ACTS had the first joint dinner during SOT annual meeting in Salt Lake City. The dinner was very successful and was a good beginning of collaboration between these two organizations. As the results, ACSOT and ACTS have agreed that we will have a joint dinner and best abstract and paper awards next year during SOT annual meeting in Baltimore. We also announced that ACSOT would organize a delegation to the 5th Congress of Toxicology for Developing Countries in Guilin and in collaboration with Chinese Journal of Pharmacology and Toxicology to publish an ACSOT issue. We have accomplished these two plans (see News below for details). I want to express my gratitude to those who made these tasks possible.

During the past year, there were so many scientific and professional achievements by our members. As you can see from the News below, Dr. Jia-Sheng Wang has not only made significant contributions in the cancer research field, but also made his scientific contribution directly benefit to Chinese. As a native of Guangxi, I feel even more personal. Dr. Charles Wang and Dr. Haizhou Zhang were elected in key official positions in the professional associations in which they are involved, respectively. I believe that their achievements reflect many accomplishes by our members, which I can not mention one by one in a short message. Please join me to congratulate them and ourselves for works well done.

Look into the future, there are many things that need our attention and efforts. Strengthening communications among our members remains my priority and a big challenge. We not only need to fulfill our commitments to have a joint dinner and best abstract and paper awards with ACTS next year during SOT annual meeting, but also to move the collaboration forward towards a potential merger between these two organizations in the foreseeable future. In addition, we need to continue our efforts to expand our collaborations with the scientists in the toxicologically related fields in China. Through our November trip, I know there are many opportunities and needs in this area. I am looking forward to working with all of you in the coming year and hopefully seeing all of you in Baltimore.

****

Call for Applications for the Best Paper/Abstract Awards

ACSOT Board

According to the decision from the joint working group of ACSOT and ACTS, the Best Paper and the Best Abstract Awards of Year 2004 will be selected and presented jointly by ACSOT and ACTS at the SOT meeting next March. We are now accepting applications for these awards. Papers may be either published or have been accepted for publication in scientific journals between October 2002 and October 2003. Abstracts may be those presented in professional meetings during the same period. Only papers/abstracts with members or perspective members of ACSOT/ACTS at the first author or senior author will be eligible for consideration. Each applicant may submit only one entry. Deadline for application is January 31, 2004. A review committee will evaluate the applications shortly after the deadline. The awards in forms of plaques will be given in the 2004 SOT meeting and the number of awards will depend upon the

number of applications. Please send your paper or abstract to: Luqi Pei (Lao Pei) at peil@cder.fda.gov, fax: 301-827-1271, or Diana Auyeung at dauyeung@sbi.criver.com, fax: 775-331-2289.

****

Summary of ACSOT's Trip to China

Zhihua Zhang

American Chinese Society of Toxicology (ACSOT)

中国旅美毒理学家协会2003年回国代表团总结

中国旅美毒理学家协会（ ACSOT ）2003年回国代表团　于11月10日至14日访问了北京大学，桂林医学院，广西医科大学并在桂林参加世界第五届发展中国家毒理学大会。 代表团共有6位成员。他们是蔡露博士 (University of Louisville)，付立杰博士 (Next Century, Inc.)，马强博士 (NIOSH)，张海洲博士 (Covance)，张治华博士 (Hoffmann-La Roche, Inc.)，赵启宇博士 (TERA)。

代表团成员于11月9日从美国到达北京并在10日上午在北京大学医学部公共卫生学院毒理学系为毒理系教师，研究生，毒理学高师班，和北京有关单位毒理学人员共八十多人作了专题学术报告。代表团成员每人用约四十五分钟时间演讲了他们的专业研究结果或研究过程和实验室管理。专题学术报告得到了热烈的反响。北京大学医学部公共卫生学院毒理系和北京有关毒理学单位领导希望中国旅美毒理学家协会今后每年都能组织这样学术交流代表团和国内同行进行交流，帮助国内同行和国外进行学术交流。代表团成员在当天下午飞往桂林和桂林医学院进行学术交流并顺道参加为期三天的世界第五届发展中国家毒理学大会。在会议期间，代表团成员在和国内外同行进行学术交流的同时，专程于12日到桂林医学院为预防医学系和药学系教师，研究生，和高年级本科生共两百多人作了专题学术报告和进行学术交流。晚上受邀游览了胜似梦幻的桂林两江四湖夜景。当然，代表团成员不会错过一切其他机会游览风景如画的桂林山水。

代表团成员于13日下午前往南宁并于14日为广西医科大学公共卫生学院和药学院教师和研究生，广西职业病防治研究所研究人员共八十多人作了专题学术报告和学术交流。专题学术报告在广西得到了同样热烈的反响，都表示获不小并希望今后中国旅美毒理学家协会（ ACSOT ）能经常组织这样学术代表团到西部来帮助西部开发和建设。

****

ACSOT/ACTS Joint Web Site Launched

Diana Auyeung

ACSOT and ACTS are pleased to announce that the joint web site of ACSOT/ACTS has been launched. The address is http://www.geocities.com/chinesetoxicologist. Thanks to Diana Auyeung and Qiyu Zhao for their time and efforts to put this web site together. An updated joint directory has been posted on the web site, but it is password protected in order to deal with the problem of our address/email list being parsed by webbots and indexed as well as spam-exploited. The password to open the file is ACTSACSOT (all capital letters). For any changes or additions to the directory, please email chinesetoxicologist@yahoo.com. The web site will contain information about the 2004 SOT meeting as it becomes available. We encourage you to visit the site and provide feedback to our Webmaster at chinesetoxicologist@yahoo.com.

****

News

ACSOT Delegation to China

A delegation of six toxicologists of ACSOT were sent to China this November. Besides attending the 5th Congress of Toxicology in Developing Countries in Guilin, Guangxi, the delegation also visited Peking University, Guilin Medical College, and Guangxi Medical University, and gave seminars at the above universities. The seminars covered different aspects of toxicology, such as drug development, risk assessment, and mechanistic studies. They were well received and welcomed by the audience. The hosts hoped that we could organize similar delegation and give seminars every year. Through these activities, ACSOT not only brought the most updated research in toxicology to its Chinese colleagues but also enhanced its exposure to and connection with different Chinese institutes. (Haizhou Zhang).

A Special Issue of Chinese Journal of Pharmacology and Toxicology

The ACSOT reached an agreement early this year with the Chinese Journal of Pharmacology and Toxicology, an official journal of the Chinese Toxicology Society, to publish a special issue of the journal containing a series of articles authored by ACSOT members. It will be published early next year (before the SOT meeting). Five papers were collected from active ACSOT members and are currently in the editorial process. These papers, including both reviews and original research papers, cover a number of important topics and are expect to attract high interest among the readership of the journal. The ACSOT Board would like to commend the efforts of the authors in supporting this special activity. (Li You and Lijie Fu).

Research of ACSOT Member Gained International Recognition

Two studies from Dr. Jia-Sheng Wang, one of the ACSOT board members, and his research group at the Division of Human Health Sciences, The Institute of Environmental and Human Health, Texas Tech University, have been selected as new findings in the American Association for Cancer Research's 2nd Annual Frontiers in Cancer Prevention Research Meeting, October 26-30, 2003, Phoenix, Arizona. The results were released to the public in a scheduled press conference in 11:30 A.M., October 28, 2003. These studies were collaborated with Guangxi Cancer Institute and Fusui Liver Cancer Institute in China. Mr. Haitao Luo, a second year PhD graduate student of Dr. Wang carried out the first study. Title of his presentation is "chemoprevention trial of green tea polyphenols in high-risk population of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine". Dr. Lili Tang, a postdoctoral research associate at Dr. Wang's group, is the leading researcher for the second study. Her presentation title is "chemoprevention trial of green tea polyphenols in high-risk population of liver cancer: modulation of aflatoxin biomarkers". These studies validated biomarkers for green tea consumption in humans, explored the modulation of green tea polyphenols on carcinogen biomarkers, and formed basis for a five year intervention study in populations of Guangxi, which is in progress. Dr. Wang's research was supported by grants from the National Institute of Environmental Health Sciences (ES11442) and the National Cancer Institute (CA90997). (Haizhou Zhang and Jasheng Wang)

ACSOT members Elected as Officers in other Organizations

Dr. Charles Y. Wang from J&J has been re-elected as an Executive Council member of Sino-American Pharmaceutical Professional Association (SAPA). Founded in 1993, SAPA is an independent and nonprofit organization with nearly 1,200 members in more than 35 states in USA, China, Hong Kong, Taiwan and Japan united by a commitment to promoting pharmaceutical science and technology and their essential roles in fostering member's career development. SAPA's headquarter is located in New Jersey with three chapters in Great Philadelphia, New England and California. In service to science, SAPA facilitates communication among scientists, policy makers, government officers, educators, and journalists from both the United States and China through its interdisciplinary conferences, symposia, section meetings, seminars, workshops and diverse publications. In service to association, SAPA Programs draw upon the foremost experts and the most current information about advances in drug discovery and development to inform analysis and discussion of public health issues, to promote scientific exchanges and networking opportunities. For details, please visit SAPA web site at http://www.sapaweb.org/. (Haizhou Zhang and Charles Y. Wang).

Dr. Haizhou Zhang from Covance has been elected as a member of the board of directors of the Genetic Toxicology Association (GTA). The GTA is a tax-exempt educational and scientific organization that was founded in 1975 and incorporated in 1981 under the laws of the state of Delaware. Its primary purpose is to promote the development of the science of genetic toxicology and to foster the exchange and dissemination of information concerning the field. The majority of members come from the mid-Atlantic and New England regions of the United States, although members from all geographic areas are welcome. Because of the geographic concentration of the majority of its members, the GTA includes professionals from a diverse

cross-section of organizations: industrial, academic, governmental and commercial. The GTA thus provides a unique and important opportunity for scientists from different types of organizations to routinely and openly exchange knowledge, ideas, views and insights. For more information about the GTA, please visit its web site at http://www.ems-us.org/who_we_are/gta/index.html. (Haizhou Zhang).

ACSOT Member Gave Presentation at Chinese SFDA Symposium

Dr. John Zhuang of Eli Lilly and Company was invited to give a presentation at the Second Symposium on Drug Evaluation sponsored by Chinese SFDA. The symposium was held on Dec. 15 and Dec. 16, 2003 in Beijing, China. About 1000 experts and scientists attended this symposium. The title of Dr. Zhuang's presentation is 'The Significance and Application of Pathology in Drug Safety Evaluation'. For more information about this symposium and current policy on drug evaluation and registration in China, please visit the web site: http://www.cde.org.cn. (Haizhou Zhang).

****

Job Opportunities

1. Pfizer:

1.1
Assoc Dir Toxicology
Morris Plains, New Jersey
Ph.D. Degree in Toxicology, or related discipline, with 10+ years of experience and board certification in toxicology.

Candidates must possess strong interpersonal skills and interact with colleagues at all levels. Ability to manage multiple projects and assignments under demanding time schedules is essential.

Job Description:

Plan, develop strategy, and evaluate and assess safety of consumer healthcare products as well as compliance with appropriate regulatory requirements. Develop and implement a safety assessment strategy for consume products for Global Marketing. Supervise, monitor, and conduct safety evaluations for product registrations in European and other Non-US markets. Review IND/NDA and 510(K) submissions, as well as evaluate Safety/Pharmacology and Pharmacokinetics of external licensing candidates and RX-to-OTC switches. Provide Pathology expertise on safety assessment of products as necessary. Represent as Toxicology expert on project teams and for multiple business groups, as well as in external meetings with regulatory authorities. Familiarity with GLP and GCP is essential. Interaction with Inter-Departmental and Inter-Divisional colleagues required at all levels.

1.2
Toxicologist
St. Louis WWSS Biochemical Toxicologist
Saint Louis, Missouri

Education Level Preferred: PhD; Majors Preferred: Pharmacology or Toxicology

Requirements:
Education and Experience: 1. Candidate must possess a Ph.D. degree in Pharmacology or Toxicology + 2-3 years of postdoctoral training in experimental toxicology. Drug discovery and development experience desirable. 2. Strong investigative toxicology background including in vitro modeling of toxicity, methods development and validation studies 3. Experience in carrying out a wide range of in vitro biochemical, sub-cellular, cell or tissue-based experimental assays 4. Ability to work well in a team environment and across diverse scientific disciplines 5.Solid interpersonal and oral and verbal communication skills required

Job Description:
The primary responsibility of this position is to design and carry out investigative toxicology studies in an effort to help position toxicity findings for compounds in Discovery or Pre-Clinical development. These studies will include development of novel in vitro models and will focus on hypothesis-driven mechanistic approaches. These studies may encompass a wide range of biochemical, sub-cellular, cell or tissue-based assay systems and endpoints. Additionally, the incumbent will function as a member of multidisciplinary discovery project and investigative toxicology teams to assist in selection of the most appropriate compounds to move forward into exploratory development.

Major Responsibilities:
1. Design and carry out mechanistic studies to evaluate the toxicity of therapeutic candidates 2. Represent Safety Sciences on Discovery project teams 3. Active participant on multi-disciplinary investigative toxicology teams

1.3
Senior Scientist I
La Jolla Discovery Biology
La Jolla, California, USA

Position Type: Full-Time

Requirements:
Ph.D. Scientist with substantial previous experience of monoclonal antibody discovery and development (industry background preferred). The candidate should demonstrate practical experience in hybridoma screening methodology, animal model efficacy studies, toxicology and biophysical characterization of lead antibodies.

Job Description:
The candidate will work with discovery and preclinical groups on a number of in-house monoclonal projects. The candidate will interact closely with Pfizer discovery groups as well as with external collaborators to identify monoclonals with potential for clinical development and support a number of projects through lead nomination.

1.4
Toxicologist
St. Louis DSE Team Toxicologist PhD
Saint Louis, Missouri, USA

Position Type: Full-Time; Education Level Preferred: PhD; Majors Preferred: Toxicology, Veterinary Pathology

Requirements:
Candidate should have a Ph.D. or equivalent in Toxicology, Veterinary Pathology (with a focus on toxicologic pathology) or related discipline, with 4 years or more of experience in drug discovery/development. Applicable board certification is a plus. Demonstrated success in contributing to early Discovery teams. While the focus is on Drug-Safety-related aspects, the successful candidate should be able to demonstrate contributions to the overall mission of the team--assessment of the target, critical review of efficacy-related aspects, selection of candidates with the best overall qualities to maximize the probability of successful development. Ability to work in a cross-functional, matrixed team environment is critical.

Job Description:
The successful candidate will represent DSE on one or more project teams, targeting selection of the most appropriate compound to move forward to CAN stage and beyond. In addition to expertise regarding the preclinical safety profile, the candidate will be expected to contribute significantly to non-toxicologic aspects of the team as well. Specific expectations include a good understanding of the molecular target, familiarity with potential adverse _class_ (therapeutic, pharmacologic, chemical) effects. The individual will design, conduct and report innovative studies to define the preliminary non-clinical safety profile. Proactive identification of potential issues, as well as proposed solutions, with an objective of predicting human risk will be a key deliverable.

2. Merck:
Research Fellow:

This position is part of the expansion of the investigative toxicology effort in Safety Assessment. The successful candidate will develop metabonomics capabilities in the laboratory using NMR spectroscopy to contribute to the characterization of mechanisms of toxicity and the identification of biomarkers to be used to assess preclinical and clinical toxicity issues.

Qualifications
The ideal candidate will possess a Ph.D. in biochemistry, pharmacology, toxicology, or equivalent. Demonstrated expertise in biochemical applications of NMR spectroscopy, including experience with high field NMR instrumentation and associated automation equipment. At least 3+ years of relevant postdoctoral experience in NMR spectroscopy are required. Experience with metabonomics is desirable.

3. Roche:
3.1

Position Code: 1457
Position Title: RESEARCH LEADER
Work Location: New Jersey - Nutley Corporate Headquarters

Major Responsibilities:
The successful candidate will provide advice, strategic planning and effective management on designated toxicology programs necessary to support the selection and timely development of potential drug candidates through close interactions with Discovery, and Nonclinical and clinical Development functions as necessary. Candidate will coordinate toxicological compound discovery and development activities locally and internationally within Roche, and externally with contract laboratories, consultants, and development partners. Candidate will be responsible for preparing contributions to internal and regulatory document (PDPs, IDBs, CTXs, INDs, NDAs, Expert Reports, etc.)

Qualifications:
DVM, PhD or equivalent advanced degree/experience in toxicology or allied field.Minimum 5 years experience in drug development (toxicology). Demonstrated ability to manage multiple scientific projects and make sound scientific interpretations/judgments. Strong interpersonal skills, and skills in collaborative problem solving, oral and written communications, project management and team interactions are required. Experience in one or more specialized areas (eg. cardiovascular safety, immunotoxicology) is advantageous.

3.2.
Position Code: 1384
Position Title: RESEARCH LEADER
Work Location: New Jersey - Nutley Corporate Headquarters

Major Responsibilities:
The successful candidate will provide advice, strategic planning and effective management for designated safety pharmacology programs necessary to support the selection and timely development of potential drug candidates through close interactions with Discovery, and Nonclinical and Clinical Development functions. Candidate will manage the safety pharmacology lab activities locally, co-ordinate internationally within Roche, and externally with contract laboratories, consultants, and development partners. Candidate will be responsible for preparing contributions to internal and regulatory documents such as PDPs, IDBs, CTXs, INDs, NDAs, etc. Candidate will be expected to provide oversite and assistance in the planning and interpretation of safety pharmacology toxicology studies.

Qualifications:
DVM, PhD or equivalent advanced degree with a minimum 5 years safety pharmacology or allied field experience, and knowledge of drug development. Must have demonstrated ability to manage multiple scientific projects and make sound scientific judgements. Strong interpersonal, oral and written skills, and experience in cardiovascular safety pharmacology required. Must have demonstrated skills in collaborative problem solving and project management. Strong managerial skills required.

3.3
Position Code: 1369
Position Title: ASSOCIATE PRINCIPAL SCIENTIST
Work Location: New Jersey - Nutley Corporate Headquarters

Major Responsibilities:
Responsible for planning, coordination, technical conduct, interpretation and reporting of data from toxicity studies in compliance with GLP regulations for the evaluation of novel therapeutic compounds. Responsibilities include: scheduling of studies, calculation of compound requirements, study supplies, coordination of outside ancillary groups and departments; coordination of other Roche centers, monitoring studies performed at CROs; development of study protocols, changes or revisions of original protocol; monitoring in-life activities such as dosing, data collection, room conditions, and adherence to protocol and SOP requirements; insuring compliance to GLP regulations, ensuring errors while performing studies are corrected and documented in data files; thorough and clear interpretation, analysis, documentation and reporting of data for in-house use and for submission to FDA or other regulatory authorities.

Qualifications:
BS/MS degree in Biology, Chemistry or a related field with a minimum of 5 years experience working in toxicology. Thorough knowledge of GLP regulations, computer literate in MS Word, EXCEL, PowerPoint, and Outlook or equivalent e-mail, and a thorough knowledge of the RAPID computer system. Applicant must have excellent interpersonal and writing skills and be able to interact with scientists at various levels in drug discovery and development. Must be able to work in a team environment.

4. JUDGE INC
4.1
TOXICOLOGIST
Job ID: JO031847
Company: JUDGE INC.
Location: CT
Contact E-mail: TCILMI@JUDGE.COM
Salary: 87,000

Description: Major Pharmaceutical Company located in CT. is seeking a Toxicologist. Candidates must have a PhD in Toxicology or related with 1-3 years experience in the Pharmaceutical Industry and completion of a formal 2 years post-doctoral in a toxicologic sub-discipline (e.g. carcinogenesis, immunology, reproductive performance).

You will conduct animal toxicology studies according to GLP, serve as a Study Toxicologist/Director on acute, sub-chronic and chronic toxicity studies and write protocols.

4.2
SCIENTIST
Job ID: JO023005
Company: JUDGE INC.

Location: NJ
Contact E-mail: TJC@JUDGE.COM
Salary: 85,000

Description: Major NJ Pharmaceutical Company is seeking a Scientist specializing in Toxicokinetics. Candidates must have a PhD in Pharmacokinetics, Toxicology or related with a minimum of 1 year of pharmaceutical industry experience.

You will interact with Toxicology in the design and interpretation of Toxicokinetic studies, integrate toxicokinetic data with toxicology data, analyze plasma concentration-time data from toxicology studies as well as preparation of necessary reports.

4.3
Job Title: REGULATORY AFFAIRS MANAGER
Job ID: JO028511
Company: JUDGE INC.
Location: GA
Contact E-mail: M_W@JUDGE.COM
Salary: 90,000 - 110,000

Description: Responsible for liaison activities w/ FDA, as well as assessment of regulatory requirements & continued review of project activities to ensure that development activities are in conformance w/ U.S. regulations, FDA guidelines & UCB policies & practices enabling the most expeditious approval of UCB products.

Job Description - PRINCIPLE DUTIES / RESPONSIBILITIES:
Participate in the development of global regulation strategies for UCB Pharma products, applying FDA's regulations, guidelines & policies to select the most effective regulatory strategy in the U.S. Liaise with regulatory agencies on behalf of UCB Pharma, either in meetings, via telephone or through written correspondence.

Ensure that all regulatory requirements are communicated to appropriate functional groups & all regulatory reporting is done within the defined timeframes as directed. Support the development of technical skills of assigned regulatory associates and staff members. Assign projects and schedule resources for direct reports. Maintain current awareness of regulations, guidelines, policies, procedures and practices and report changes to appropriate personnel. Advise management regarding the status of all regulatory activities related to development and other projects.

Required Experience
REQUIREMENTS:
More than 10 years of both domestic and international regulatory affairs experience or other related technical experience in the industry, ability to work on projects independently and effectively manage and direct personnel participating on development project teams. At least 3 years management experience directing and supervising "Manager" or "Senior Associate" level personnel. Demonstrated working knowledge of regulatory process and technical competence in

core areas of drug development: clinical, toxicology, pharmacy and CMC. Must have previous IND or NDA experience as well as significant liaison experience with FDA or other

4.4
Job Title: PHARMACOLOGIST
Job ID: JO031713
Company: JUDGE INC.
Location: NJ
Contact E-mail: TCILMI@JUDGE.COM
Salary: 120,000 - 140,000
Description: Major NJ Pharmaceutical company is seeking a Research Leader for Safety Pharmacology. Candidates must have a PhD and a minimum of 5 years pharmaceutical industry experience in Safety Pharmacology for drug development. In addition, strong managerial skills is required.

You will provide advice, strategic planning and effective management for designated safety pharmacology programs necessary to support the selection and timely development of potential drug candidates through close interactions with Discovery and Non Clinical Development functions for Cardiovascular Research. In addition, you will be expected to provide oversite and assistance in the planing and interpretation of safety pharmacology toxicology studies and the preparation to internal and regulatory documents.

4.5
Job Title: DIRECTOR
Job ID: JO031741
Company: JUDGE INC.
Location: NJ
Contact E-mail: RLP@JUDGE.COM
Salary: 140,000 - 160,000
Description: Executive Director Preclinical Drug Development and Project Management Minimum educational requirement is a PhD in Chemistry, Biochemistry, Pharmacokinetics, Drug Metabolism, or Toxicology.Must have over 10 years experience in the pharmaceutical industry, preferably with direct experience working with central nervous system (CNS) drug discovery and development. Candidates with regulatory document experience and a proven record of data management will be preferred.

The individual will have two primary areas of responsibility; 1) oversee and direct the efforts in Preclinical Drug Development and 2) the responsibility of Project Management. Responsibilities:
. Oversee and direct efforts in PDD, currently a group of 11 individuals.
. Expertise in the early profiling of drugs for pharmaceutical properties.
. Ability to direct efforts in drug absorption, metabolism and all aspect of pharmacokinetics and pharmacodynamics (ADMET/PK/PD).
. Candidate should have an understanding of toxicology and a command of the integrative and coordinated role of these disciplines in drug discovery and development is also essential. Coordination of these efforts to expeditiously and appropriately move compounds through the various phases of drug discovery and development, together with a clear understanding of the

formal requirements for early clinical CNS drug development, will be a critical aspect of this position.
. Position requires working closely with other disciplines which include: Medicinal Chemistry, Behavior and Neurophysiology, Assay Development and Screening.
. Efforts will also include working with outside vendors and Contract Research Organizations (CROs) with more advanced compounds.
. Project Management initiatives include the direction and coordination of drug development projects through Phase IIa.
. Project Management responsibilities will require working with various CROs, monitoring and implementing all activities.

4.6
Job Title: ASSOCIATE DIRECTOR
Job ID: JO031843
Company: JUDGE INC.
Location: CT
Contact E-mail: TCILMI@JUDGE.COM
Salary: 140,000
Description: Major Pharmaceutical Company located in New England is seeking an Associate Director of Toxicology and Safety Assessment. Candidates must have a PhD in Toxicology or Pathology with 10 years experience within the pharmaceutical industry. In addition, extensive experience in managing toxicology studies at all stages of development, project team representation and international regulatory requirements is required.

You will manage a group of approximately 20 - 30 FTE's focused on conducting regulatory toxicology studies in support of NCE's or Biologics in all stages of development including, Study Directors which conduct the toxicology studies and represent all Discovery and Development projects; a toxicology laboratory which includes technicians that perform dosing and collection of all antemortem data; and, contracts and licensing. In addition, you would be responsible for ensuring that all animal toxicology studies are conducted according to GLP, that studies comply with FDA, EPA, OSHA and company policies, propose mechanistic toxicity studies when appropriate and serve as a Study Director when necessary

5. Texas Tech University

Postdoctoral Position

A postdoctoral associate position is available immediately to work on research projects related to develop and validate molecular biomarkers of various carcinogens in animal models and high-risk human populations at the Institute of Environmental and Human Health, Texas Tech University. Applicants should have a doctoral degree in biomedical sciences. Experience in molecular biology and biological/analytical chemistry is preferred. Please send a C.V. and the names, telephone numbers, and e-mail addresses of three references to: Dr. J-S Wang (js.wang@ttu.edu), Box 41163, TIEHH, Texas Tech University, Lubbock, TX 79409. Tel. (806) 885-0320; Fax. (806) 885-2132.